Search Results - "Jun, Yearin"

Next-generation proteasome inhibitors for cancer therapy by Park, Ji Eun, Miller, Zachary, Jun, Yearin, Lee, Wooin, Kim, Kyung Bo

“…Over 2 decades ago, the proteasome was considered a risky or even untenable therapeutic target. Today, proteasome inhibitors are a mainstay in the treatment of…”
Get full text

Quinic Acid‐Conjugated Nanoparticles Enhance Drug Delivery to Solid Tumors via Interactions with Endothelial Selectins by Xu, Jun, Lee, Steve Seung‐Young, Seo, Howon, Pang, Liang, Jun, Yearin, Zhang, Ruo‐Yu, Zhang, Zhong‐Yin, Kim, Pilhan, Lee, Wooin, Kron, Stephen J., Yeo, Yoon

“…Current nanoparticle (NP) drug carriers mostly depend on the enhanced permeability and retention (EPR) effect for selective drug delivery to solid tumors…”
Get full text

Lower hepatotoxicity risk in Xelaglifam, a novel GPR40 agonist, compared to Fasiglifam for type 2 diabetes therapy by Yoon, Jongmin, Song, Haengjin, Park, Ji Soo, Kim, Jeong Ho, Jun, Yearin, Gim, Sang-Ah, Hong, Changhee, An, Kyung Mi, Park, Joon-Tae, Lee, Jung Woo, Yoon, Hongchul, Kim, Yun Seok, Kim, Sang Geon

“…Fasiglifam, a candidate targeting GPR40, showed efficacy in clinical trials for type 2 diabetes but exerted liver toxicity. This study investigated the…”
Get full text

Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation by Park, Ji Eun, Park, Joonyoung, Jun, Yearin, Oh, Yunseok, Ryoo, Gongmi, Jeong, Yoo-Seong, Gadalla, Hytham H, Min, Jee Sun, Jo, Jung Hwan, Song, Myung Geun, Kang, Keon Wook, Bae, Soo Kyung, Yeo, Yoon, Lee, Wooin

“…Carfilzomib (CFZ) is the second-in-class proteasome inhibitor with much improved efficacy and safety profiles over bortezomib in multiple myeloma patients. In…”
Get full text

122-LB: In Vitro Pharmacodynamic Studies of IDG-16177, a Potent GPR40 Agonist, for the Treatment of Type 2 Diabetes by YOON, JONGMIN, SONG, HAENGJIN, LEE, DON-GIL, KIM, JUNG HO, HONG, DAHAE, SHIN, CHORONG, JANG, EUNHYE, KIM, JISU, LEE, SEOLHEE, JUN, YEARIN, AN, KYUNGMI, HONG, CHANG-HEE, KWAK, HYUN-JUNG, JE, IN-GYU, SONG, HYO-JUNG

“…G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1), a clinically validated anti-diabetes target, enhances insulin secretion in type 2 diabetes. It is known that…”
Get full text

123-LB: IDG-16177, a Potent, Orally-Bioavailable GPR40 Agonist, Improves Glycemic Control and Glucose-Stimulated Insulin Secretion in Preclinical Studies by YOON, JONGMIN, LEE, DON-GIL, KIM, JUNG HO, HONG, DAHAE, SHIN, CHORONG, JANG, EUNHYE, KIM, JISU, SONG, HAENGJIN, LEE, SEOLHEE, JUN, YEARIN, AN, KYUNGMI, HONG, CHANG-HEE, KWAK, HYUN-JUNG, JE, IN-GYU, SONG, HYO-JUNG

“…GPR40/FFAR1 is a G-protein-coupled receptor predominantly expressed in pancreatic β-cells. GPR40 agonists are known to stimulate insulin secretion and reduce…”
Get full text

124-LB: Development of IDG-16177, a Selective and Safe GPR40 Agonist for the Treatment of Type 2 Diabetes by YOON, JONGMIN, SONG, HAENGJIN, KIM, JUNG HO, LEE, SEOLHEE, SHIN, CHORONG, JUN, YEARIN, HONG, DAHAE, LEE, DON-GIL, JANG, EUNHYE, KIM, JISU, AN, KYUNGMI, HONG, CHANG-HEE, KWAK, HYUN-JUNG, JE, IN-GYU, SONG, HYO-JUNG

“…GPR40 has been considered a potential therapeutic target for type 2 diabetes because activation of GPR40 stimulates insulin secretion when glucose levels…”
Get full text

644-P: Discovery of Nonpeptide, Orally Available Small Molecule GLP-1 Receptor Agonists by IM, A-RANG, PARK, JUNG-EUN, HONG, DAHAE, JE, IN-GYU, KIM, JUNG HO, CHANG, MIN WHAN, HONG, CHANG-HEE, SHIN, JAE EUI, SOHN, TE-IK, JUN, YEARIN, JANG, EUNHYE, YOO, YEONGRAN, JEON, WOOJIN, AN, KYUNGMI

“…GLP-1R agonists comprise a growing class of agents that deliver unprecedented efficacy in the treatment of diabetes. We discovered promising compounds for the…”
Get full text